Figure 1.

Treatment protocol (St. Jude Children's Research Hospital Total XIII B) for ALL in a patient who developed t-AML (Upper). The time of t-AML diagnosis is indicated by an arrow. The interval corresponding to each therapy block is indicated in gray scale boxes (Upper) and corresponds with the time line in days (Lower). The times of administration of topoisomerase II inhibitors (etoposide, 300 mg/m² ▿, and daunorubicin, 25 mg/m² Δ), asparaginase, 10,000 units/m² thrice weekly × six doses (■), and G-CSF (|) are indicated. MLL-ENL genomic clone frequencies (Lower) for bone marrow (■) and for peripheral blood samples (□). N.D., not detected.